
HélÃ"ne Fe Gleitz

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/545010/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Heterogeneous bone-marrow stromal progenitors drive myelofibrosis via a druggable alarmin axis. Cell Stem Cell, 2021, 28, 637-652.e8.	11.1	92
2	A novel adeno-associated virus capsid with enhanced neurotropism corrects a lysosomal transmembrane enzyme deficiency. Brain, 2018, 141, 2014-2031.	7.6	80
3	Brainâ€ŧargeted stem cell gene therapy corrects mucopolysaccharidosis type II via multiple mechanisms. EMBO Molecular Medicine, 2018, 10, .	6.9	66
4	Macrophage enzyme and reduced inflammation drive brain correction of mucopolysaccharidosis IIIB by stem cell gene therapy. Brain, 2018, 141, 99-116.	7.6	64
5	Increased CXCL4 expression in hematopoietic cells links inflammation and progression of bone marrow fibrosis in MPN. Blood, 2020, 136, 2051-2064.	1.4	56
6	Identification of age-dependent motor and neuropsychological behavioural abnormalities in a mouse model of Mucopolysaccharidosis Type II. PLoS ONE, 2017, 12, e0172435.	2.5	20
7	Still a burning question: the interplay between inflammation and fibrosis in myeloproliferative neoplasms. Current Opinion in Hematology, 2021, 28, 364-371.	2.5	17
8	Understanding deregulated cellular and molecular dynamics in the haematopoietic stem cell niche to develop novel therapeutics for bone marrow fibrosis. Journal of Pathology, 2018, 245, 138-146.	4.5	16
9	An Improved Adeno-Associated Virus Vector for Neurological Correction of the Mouse Model of Mucopolysaccharidosis IIIA. Human Gene Therapy, 2019, 30, 1052-1066.	2.7	13
10	Genetic barcoding systematically compares genes in del(5q) MDS and reveals a central role for <i>CSNK1A1</i> in clonal expansion. Blood Advances, 2022, 6, 1780-1796.	5.2	7
11	Isolation of human bone marrow stromal cells from bone marrow biopsies for single-cell RNA sequencing. STAR Protocols, 2021, 2, 100538.	1.2	3
12	Transcriptional Landscape of the Microenvironment in Bone Marrow Fibrosis at Single Cell Level. Blood, 2019, 134, 1675-1675.	1.4	2
13	Whole body correction of severe mucopolysaccharidosis type II by lentiviral-mediated stem cell gene therapy with blood-brain barrier-crossing peptides. Molecular Genetics and Metabolism, 2017, 120, S56-S57.	1.1	1
14	Brain targeted stem cell gene therapy provides long-term correction of mucopolysaccharidosis type II. Molecular Genetics and Metabolism, 2019, 126, S31-S32.	1.1	1
15	Fibrosis driving myofibroblast precursors in MPN and new therapeutic pathways. HemaSphere, 2019, 3, 142-145.	2.7	1